Ocular surface mucins (mucomimetic effect)

Ocular surface hydration via mucomimetic effect" is not a canonical molecular target but rather describes a therapeutic strategy aimed at improving or restoring the hydration and lubrication of the ocular surface by mimicking or enhancing natural mucin functions. The healthy ocular surface relies on both secreted and membrane-associated mucins—primarily glycoproteins such as MUC1, MUC4, MUC16 (membrane-bound), and especially MUC5AC (secreted by conjunctival goblet cells)—to maintain wettability, provide lubrication during blinking, form a protective barrier against pathogens/debris, and stabilize the tear film[1][2]. In dry eye disease, reduced goblet cell numbers and decreased mucin production lead to impaired hydration. Mucomimetic agents are designed to either stimulate endogenous mucin secretion/goblet cell proliferation or act as synthetic/semisynthetic polymers that mimic natural mucins' lubricating properties. Examples include diquafosol—a P2Y₂ receptor agonist that stimulates both fluid and mucin secretion—and rebamipide—which increases goblet cell numbers. Some artificial tears use polymers like hydroxypropyl guar or tamarind seed polysaccharide for their mucoadhesive/mucomimetic properties to enhance tear film stability by forming hydrated scaffolds over the epithelium[3][4][7]. Because "ocular surface hydration via mucomimetic effect" is not an individual molecule/receptor but instead refers broadly to this mechanism/class-based approach for treating dry eye disease through enhancement/mimicry of natural mucus layers on the eye's exterior, it should not be considered a canonical therapeutic target in molecular pharmacology terms. Instead, it encompasses multiple targets—including P2Y₂ receptors for diquafosol or TRKA receptors for experimental drugs like MIM-D3—as well as non-receptor-based physical/chemical strategies using polymeric agents. In summary: > "Ocular surface hydration via mucomimetic effect" describes an approach leveraging either stimulation of endogenous ocular-surface mucins or application of synthetic analogs/polymers with similar biophysical properties to restore lubrication/wettability in conditions such as dry eye disease—not a discrete molecular entity suitable for structured database targeting.[1][2][3]

Other names

Mucomimetic agentsMucin mimeticsOcular surface hydration via mucomimetic effectArtificial tear mucomimetics

Stimulation of mucin secretion from conjunctival goblet cells[2][5]; Enhancement of goblet cell differentiation[5]